Vectus Biosystems
Vectus Biosystems is an Australian clinical-stage biotechnology company developing first-in-class small-molecule antifibrotic therapies, with lead compound VB0004 in clinical testing for idiopathic pulmonary fibrosis, targeting fibrotic diseases of the heart, kidneys, lungs, and liver.
- Company typePublic
- Founded2005
- HeadquartersSydney, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vectus Biosystems does
Vectus Biosystems Limited (ASX: VBS) is an Australian clinical-stage biotechnology company founded in 2005 and headquartered in Rosebery, Sydney, with research operations in North Ryde. The company develops small-molecule therapeutics targeting fibrotic diseases affecting the heart, kidneys, lungs, and liver, building on founder Dr Karen Duggan's research into a naturally occurring molecule capable of reversing fibrosis. Its lead compound, VB0004, is a first-in-class antifibrotic candidate for idiopathic pulmonary fibrosis (IPF) that has demonstrated reversal of established fibrosis in preclinical models and has completed Phase 1a clinical studies with a favorable safety and pharmacokinetic profile. The company also owns a broader library of more than 200 small molecules with anti-hypertensive and anti-fibrotic properties, and operates a wholly-owned subsidiary, Accugen Pty Limited, which provides a qPCR quantification platform for DNA/RNA measurement.
Vectus is pre-revenue in its core therapeutic pipeline and operates on a licensing and asset-sale business model, exemplified by the April 2026 sale of its renal anti-fibrotic program VB4-P5 to XORTX Therapeutics for US$3.0 million in shares and warrants, and by a 2025 licensing agreement with an international biotechnology company for a renal fibrosis asset. The company's near-term go-to-market is regulatory-driven rather than commercial: it engaged CHRS as its US regulatory agent in July 2026 to handle FDA submissions, signalling intent to pursue US approvals for its pipeline. Customers are effectively pharmaceutical partners and licensing counterparties rather than end-patient consumers, and the company markets itself through ASX announcements, an investor centre, and its website rather than traditional sales channels. The Accugen subsidiary operates as a separate diagnostics platform business with its own website and product page.
The business is run by a small leadership team headed by CEO and CTO Dr Tara Speranza, with non-executive chairman Dr Ronald Shnier, deputy chairman Mr Maurie Stang, director Ms Linda Walters, founder Dr Karen Duggan, and company secretary Mr Robert Waring. Vectus is incorporated as a public limited company in Australia (ABN 54 117 526 137) and trades on the ASX under the ticker VBS with a distributed public shareholder base and no parent company identified.
Vectus Biosystems firmographics
Firmographics- Name
- Vectus Biosystems
- Legal name
- Vectus Biosystems Limited
- Website
- https://vectusbiosystems.com.au
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Vectus Biosystems is an Australian clinical-stage biotechnology company developing first-in-class small-molecule antifibrotic therapies, with lead compound VB0004 in clinical testing for idiopathic pulmonary fibrosis, targeting fibrotic diseases of the heart, kidneys, lungs, and liver.
- Ownership category
- akta.pro rank
Where Vectus Biosystems is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
Vectus Biosystems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Licensing and Asset Sales: Vectus generates revenue through licensing agreements and asset sales to larger pharmaceutical companies. The company sold its renal anti-fibrotic program (VB4-P5) to XORTX Therapeutics for US$3.0 million through issuance of shares and warrants, demonstrating a pathway for potential milestone and royalty revenues from similar arrangements.
- Pharmaceutical Development: Pre-revenue clinical-stage biotech developing lead compound VB0004 for idiopathic pulmonary fibrosis. Revenue expected upon successful clinical development and regulatory approval.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Vectus Biosystems product offering
Product offeringCore offering
Vectus Biosystems is an Australian clinical-stage biotechnology company developing novel small molecule therapies for fibrotic diseases, with a primary focus on advancing its lead compound VB0004 for idiopathic pulmonary fibrosis (IPF). VB0004 is a first-in-class antifibrotic candidate that has demonstrated the ability to reverse established fibrosis in preclinical models and has completed Phase 1a clinical studies with a favorable safety and pharmacokinetic profile. The company also operates a wholly-owned subsidiary, Accugen Pty Limited, which offers a molecular diagnostics qPCR quantification platform comprising reagents and software for measuring DNA or RNA in samples.
Product overview
Vectus Biosystems is a clinical-stage biotechnology company developing novel therapies for fibrotic diseases. The company operates with a lead compound approach, centered on VB0004 for idiopathic pulmonary fibrosis (IPF), supported by a platform technology library of over 200 small molecules with anti-hypertensive and anti-fibrotic properties targeting the heart, kidneys, lungs, and liver. Additionally, the company's wholly-owned subsidiary Accugen Pty Limited offers a separate qPCR quantification platform (Accugen) for measuring DNA/RNA in samples. The company sold its kidney anti-fibrotic asset (VB4-P5) to XORTX Therapeutics in April 2026.
Differentiator
Problem solved
Functional benefit
Products and services
- VB0004
Quantifiable outcome
- Reversal of established fibrosis in preclinical models
- +2 more outcomes
Companies that use Vectus Biosystems
Customer profileSegments3 records
Ideal customer profiles2 records
Vectus Biosystems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Vectus Biosystems partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- CHRSminorVectus engaged CHRS as its regulatory agent to handle FDA submission processes. This marks a procedural step toward potential U.S. regulatory approvals for the company's therapeutic programs.
- XORTX Therapeutics Inc.coreXORTX acquired Vectus' Renal Anti-Fibrotic Therapeutic Program including novel chemical entity VB4-P5, associated intellectual property, regulatory documentation, and manufacturing data for US$3.0 million. The program targets both rare and prevalent forms of chronic kidney disease characterized by fibrosis. Deal was initially announced via binding term sheet on October 17, 2025 and closed in April 2026.
- ServierminorCEO Dr Tara Speranza led a successful commercial partnership with Servier during her academic career at University of Sydney and University of Geneva, resulting in development and commercialisation of the anti-osteoporotic therapy Protelos.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Vectus Biosystems competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights6 records
Customer concentration
Vectus Biosystems social profiles
Digital presenceVectus Biosystems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vectus Biosystems leadership team
Management profileNumber of profiles
Profiles6 records
Vectus Biosystems subsidiaries and ownership
Company hierarchySubsidiaries1 record
Vectus Biosystems funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vectus Biosystems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vectus Biosystems
What does Vectus Biosystems do?
Vectus Biosystems is an Australian clinical-stage biotechnology company developing novel small molecule therapies for fibrotic diseases, with a primary focus on advancing its lead compound VB0004 for idiopathic pulmonary fibrosis (IPF). VB0004 is a first-in-class antifibrotic candidate that has demonstrated the ability to reverse established fibrosis in preclinical models and has completed Phase 1a clinical studies with a favorable safety and pharmacokinetic profile. The company also operates a wholly-owned subsidiary, Accugen Pty Limited, which offers a molecular diagnostics qPCR quantification platform comprising reagents and software for measuring DNA or RNA in samples.
Is Vectus Biosystems a public or private company?
Vectus Biosystems is a public company. It is classified as public and is currently operating.
When was Vectus Biosystems founded?
Vectus Biosystems was founded in 2005. It employs 1 to 10 people.
Where is Vectus Biosystems based?
Vectus Biosystems is headquartered in Sydney, Australia, in the Oceania region.
How does Vectus Biosystems make money?
Two revenue lines are on record. Licensing and Asset Sales are the primary driver. The others are pharmaceutical Development.
Does Vectus Biosystems have an API?
No public API is recorded for Vectus Biosystems.